Brafix
Brafix Price range: $ 11,00 through $ 29,00
Back to products
Cialis Strips
Cialis Strips Price range: $ 50,00 through $ 140,00

Charboleps

Price range: $ 6,00 through $ 14,00

Charboleps is a highly effective medication primarily utilized for the management of various neurological conditions. It serves as a reliable anticonvulsant, helping to control and prevent different types of seizures in patients with epilepsy. Additionally, this medication is widely recognized for its ability to relieve the intense facial pain associated with trigeminal neuralgia. Charboleps also plays a significant role in stabilizing mood and managing acute manic episodes in individuals diagnosed with bipolar disorder. This pharmaceutical-grade formula ensures consistent therapeutic results for patients seeking to improve their daily quality of life.

Active substance: Herbal
SKU: Charboleps Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Charboleps – Information for Patients and Caregivers

Charboleps belongs to a class of medications known as anticonvulsants or antiepileptic drugs. It is primarily prescribed by healthcare professionals to manage specific types of seizure disorders, such as partial seizures, as well as distinct neuropathic pain conditions like trigeminal neuralgia.

Because Charboleps is a prescription-only pharmaceutical in the United States, its administration requires close clinical monitoring and individualized dosing under the supervision of a licensed physician.

Attribute Details
Active Ingredient (INN) Carbamazepine
Therapeutic Class Anticonvulsant / Antiepileptic Agent
Prescription Status Prescription (Rx) only
Route of Administration Oral
Primary Purpose Management of seizure disorders and trigeminal neuralgia
Storage Conditions Room temperature (20°C to 25°C / 68°F to 77°F) away from moisture

How the drug works

Charboleps exerts its therapeutic effect by stabilization of hyperexcitable neuronal membranes, inhibition of repetitive neuronal discharges, and reduction of synaptic propagation of excitatory impulses. The active substance, carbamazepine, acts principally by blocking voltage-gated sodium channels in neurons during high-frequency firing. By binding to the inactivated state of these sodium channels, the drug prevents rapid, sustained firing of action potentials without altering normal resting neuronal conductivity.

In addition to its sodium-channel blockade, carbamazepine modulates presynaptic release of glutamate and alters adenosine receptor activity. These combined neurochemical actions suppress aberrant electrical signals in the central nervous system, helping control epileptic focus activity and alleviating paroxysmal pain signals associated with cranial neuralgias.

What it’s used for

Charboleps is FDA-approved for specific clinical indications. Its primary neurologic indication is the treatment of epilepsy, specifically partial seizures with complex symptomatology (psychomotor or temporal lobe seizures), generalized tonic-clonic (grand mal) seizures, and mixed seizure patterns. It is not indicated for absence seizures (petit mal), as it may exacerbate these conditions.

Additionally, Charboleps is indicated for the treatment of true trigeminal neuralgia (tic douloureux) to relieve intense paroxysmal facial pain, as well as glossopharyngeal neuralgia. Any off-label applications, such as off-label use for certain psychiatric conditions or secondary mood stabilization, must be evaluated solely by a qualified prescriber based on specific patient risk profiles and therapeutic necessity.

Dosing schedule

Dosing of Charboleps must be highly individualized by the prescribing physician. Therapy typically initiates at a low starting dose, which is gradually titrated upward until optimal clinical response or target plasma concentration is achieved. For adults with epilepsy, treatment often begins with 200 mg taken twice daily, with incremental increases authorized at weekly intervals depending on clinical response and tolerability.

Administration should occur with meals to minimize gastrointestinal discomfort. Tablets or oral formulations must be taken consistently at regular intervals to maintain stable therapeutic plasma levels. Patients should never adjust their dosage or discontinue therapy abruptly without explicit guidance from their physician, as sudden cessation increases the risk of precipitating status epilepticus or breakthrough seizures.

What happens in the body

Following oral administration, carbamazepine is absorbed relatively slowly but adequately from the gastrointestinal tract. Peak plasma concentrations are typically reached within 4 to 24 hours depending on the specific formulation (immediate-release versus extended-release). The drug binds extensively to plasma proteins, predominantly albumin and alpha-1-acid glycoprotein, with a protein binding rate of approximately 75% to 90%.

Metabolism occurs extensively in the liver, primarily mediated by the cytochrome P450 enzyme system, specifically the CYP3A4 isozyme. A primary active metabolite, carbamazepine-10,11-epoxide, possesses anticonvulsant properties of its own. Notably, carbamazepine induces its own metabolism (auto-induction), which reduces its elimination half-life from an initial 30 to 40 hours down to approximately 12 to 24 hours after repeated dosing. Excretion occurs mainly via the kidneys as metabolites, with a small percentage excreted in feces.

What to avoid while taking it

Patients taking Charboleps must observe specific dietary restrictions. Grapefruit and grapefruit juice significantly inhibit hepatic CYP3A4 enzymes, which can markedly elevate blood levels of carbamazepine and increase the probability of severe adverse effects or toxicity. Therefore, concurrent consumption of grapefruit products should be avoided entirely during treatment.

Alcohol consumption must be strictly limited or avoided. Concomitant use of alcohol and Charboleps can enhance central nervous system depression, leading to severe drowsiness, impaired coordination, altered judgment, and potential respiratory compromise. Furthermore, alcohol may lower the seizure threshold, counteracting the therapeutic goal of epilepsy management.

Compatibility with other medicines

Charboleps exhibits a complex drug interaction profile due to its potency as a metabolic enzyme inducer. It induces CYP1A2, CYP2C9, CYP3A4, and UDP-glucuronosyltransferases, which accelerates the clearance of numerous co-administered drugs. For instance, it decreases the efficacy of hormonal contraceptives, oral anticoagulants (such as warfarin), certain antiarrhythmics, antiretrovirals, and immunosuppressants. Women of childbearing potential taking hormonal birth control must discuss non-hormonal barrier methods with their provider.

Conversely, drugs that inhibit CYP3A4–including macrolide antibiotics (such as erythromycin), azole antifungals (such as ketoconazole), fluoxetine, and calcium channel blockers–can increase carbamazepine plasma concentrations to toxic levels. Co-administration with monoamine oxidase inhibitors (MAOIs) is strictly contraindicated and requires a minimum 14-day washout period between therapies.

Adverse reactions

Adverse effects associated with Charboleps range from mild transient symptoms to severe systemic reactions. Common nervous system effects during therapy initiation include dizziness, drowsiness, unsteadiness (ataxia), fatigue, and diplopia (double vision). Gastrointestinal symptoms such as nausea, vomiting, dry mouth, and abdominal distress may also occur, though these often subside as tolerance develops over time.

Less common but serious adverse events involve dermatologic, hematologic, and hepatic systems. Dermatologic manifestations include mild erythematous rashes, though serious cutaneous reactions like Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) may develop. Hematologic risks include transient leukopenia, aplastic anemia, and agranulocytosis. Hepatic enzyme elevations, hyponatremia due to inappropriate antidiuretic hormone secretion (SIADH), and hypersensitivity reactions also warrant vigilance.

Important precautions

Charboleps carries serious boxed warnings regarding dermatologic reactions and blood dyscrasias. Genetic screening for the HLA-B*1502 allele is strongly recommended prior to initiating therapy in patients of Asian ancestry, as this genetic marker is strongly associated with a significantly elevated risk of developing Stevens-Johnson syndrome or toxic epidermal necrolysis. Patients possessing the HLA-A*3101 allele are also at increased risk for hypersensitivity syndromes.

Special monitoring is required in elderly patients due to an elevated susceptibility to hyponatremia, confusion, and cardiovascular effects. In pregnancy, Charboleps is classified as carrying risk; exposure during the first trimester increases the incidence of major congenital malformations, including neural tube defects (such as spina bifida). Prescribers must weigh clinical benefits against fetal risks and monitor serum folate levels. Breastfeeding is generally monitored closely, as carbamazepine passes into human breast milk.

Red flags

Certain symptoms mandate urgent emergency medical evaluation. Patients should seek immediate medical attention if they experience signs of severe skin reactions, such as fever accompanied by a spreading rash, skin peeling, or mucosal blistering around the mouth, eyes, or genitals. Sudden unexplained sore throat, fever, mouth ulcers, or unusual bruising and petechiae can indicate severe bone marrow suppression.

Emergency care is also necessary if a patient develops signs of acute hepatic dysfunction–including jaundice (yellowing of the eyes or skin), dark urine, and severe right upper quadrant abdominal pain–or signs of severe hyponatremia, such as profound confusion, extreme lethargy, or seizures. Any emergence of suicidal ideation or sudden severe mood changes warrants prompt psychiatric and medical intervention.

If you skip a dose

If a patient misses a scheduled dose of Charboleps, it should be taken as soon as remembered. However, if it is almost time for the next scheduled administration, the missed dose should be skipped entirely, and the regular dosing routine resumed. Patients must never double the dose or take extra medication to compensate for a missed dose, as this significantly increases the risk of acute drug toxicity and CNS depression.

Storage and expiration

Charboleps should be stored at controlled room temperature, ideally between 20°C and 25°C (68°F to 77°F), with brief excursions permitted between 15°C and 30°C (59°F to 86°F). The medication must be kept in its original, tightly closed container to protect it from excessive light and high humidity. Avoid storing tablets in humid environments such as bathrooms.

Keep all pharmaceuticals out of the reach and sight of children and pets. Do not use the medication past the expiration date printed on the packaging. Unused or expired medication should be disposed of via proper pharmacy take-back programs or in accordance with local drug disposal guidelines rather than flushed down the toilet.

Common questions

Q: Why are routine blood tests required while taking Charboleps?
A: Prescribers order periodic complete blood counts (CBC), liver function panels, and serum electrolyte levels to monitor for potential adverse effects such as leukopenia, hepatic enzyme elevation, or hyponatremia. Monitoring therapeutic blood levels also ensures the drug remains within the effective and safe plasma concentration range.

Q: Can Charboleps affect the performance of hormonal birth control?
A: Yes. Carbamazepine accelerates the hepatic metabolism of estrogen and progestin components in oral contraceptives, patches, and implants. Patients using hormonal contraception should consult their physician regarding alternative, reliable non-hormonal barrier methods of birth control.

Q: Is it safe to drive or operate machinery after starting Charboleps?
A: Charboleps frequently causes somnolence, dizziness, blurred vision, and altered reaction times, particularly during the initial weeks of treatment. Patients should refrain from driving, operating heavy machinery, or engaging in hazardous tasks until they are certain the medication does not impair their cognitive or motor abilities.

Q: What should I do if I plan to become pregnant while on Charboleps?
A: You should consult your prescribing physician immediately before planning a pregnancy. Because carbamazepine carries risks of congenital malformations, your doctor will evaluate whether to adjust dosing, switch therapies, or initiate supplemental folic acid prior to conception.

Q: Can I stop taking Charboleps if my seizures or facial pain stop?
A: No. Abruptly stopping Charboleps can trigger rebound seizures, status epilepticus, or sudden recurrence of severe neuralgia. Any discontinuation or dose reduction must be performed gradually under the direct supervision of your healthcare provider.

Information on this page is for reference and does not replace an assessment by a licensed healthcare professional. In accordance with FDA requirements.

Additional information
Dosage

60 caps

Package

1 bottles

,

2 bottles

,

3 bottles

Ενεργός Ουσία